FDA Clearance Tracker · N970012-S196
AMS 700 Inflatable Penile Prosthesis, AMS 700 Inflatable Penile Prosthesis with InhibiZone, AMS Ambicor Inflatable Pe
Last checked: Nov 20, 2026Latest source record: Sep 20, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Sep 20, 2023
Approved
Time to decision
180 days
Received Mar 24, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- N970012-S196
- Device name
- AMS 700 Inflatable Penile Prosthesis, AMS 700 Inflatable Penile Prosthesis with InhibiZone, AMS Ambicor Inflatable Pe
- Applicant
- Boston Scientific Corp
- Applicant location
- Marlboro, MA
- Received
- Mar 24, 2023
- Decided
- Sep 20, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- N970012
Device type
- Device type
- Prosthesis, penis, inflatable (JCW)
- Device class
- Class III
- Regulation
- 21 CFR 876.3350
- Specialty
- GI, Urology & Nephrology
FDA's approval statement
As written in FDA's record.
Approval for 1) an update to the AMS 700 product labeling to include an alternative implant location for the AMS 700 reservoir. The AMS 700 reservoir is a component of the AMS 700 system and is available with or without the drug treatment known as InhibiZone; and 2) an update to the AMS 700 product labeling and the AMS Ambicor product labeling to include new parameters for safe magnetic resonance scanning of a patient implanted with an AMS 700 system or an AMS Ambicor device.
Source documents
Other decisions for Boston Scientific Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P130030 · Decided Mar 10, 2026 · 4,453 days after receipt
Device type: STENT, CORONARY (MAF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.